Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAnesthesiologyPremera Bluecross IV Anesthetics Coverage Update |…
    Ask Trek AI about this page
    CurrentPremera BluecrossPolicy 5.01.586

    Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.586 alerts

    Get alerted when Policy 5.01.586 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage position for intravenous infusion of anesthetics (e.g., ketamine, lidocaine) when used to treat chronic pain syndromes (including neuropathic pain, chronic daily headache, fibromyalgia) and psychiatric disorders (including depression, anxiety, OCD, PTSD, and substance use disorders). Also lists applicable CPT/HCPCS codes and summarizes evidence and guidance.

    Policy Summary
    PayerPremera Bluecross
    PolicyIntravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders
    Policy CodePolicy 5.01.586
    Change TypeAnnual literature reviewcoding update
    Effective Date
    Last ReviewMay 1, 2026
    Next Review Date
    Key ActionClaims for IV infusion of anesthetics (e.g., ketamine, lidocaine) for chronic pain or psychiatric/substance use disorders are considered investigational and not covered; providers should document indication but expect denial if submitted for these indications.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Policy updated with literature review through October 1, 2025; policy statements unchanged.

    Initial policy replaced prior policy 5.01.16 and expanded to include IV ketamine for psychiatric symptoms and disorders in earlier history.

    3Investigational indications listed
    6CPT/HCPCS codes referenced
    100+Clinical trials on ketamine (ClinicalTrials.gov)

    Coverage Summary

    Overview: Policy 5.01.586 defines the coverage position for intravenous anesthetics (e.g., ketamine, lidocaine) when used to treat chronic pain syndromes (including neuropathic pain, chronic daily headache, fibromyalgia) and psychiatric disorders (including depression, anxiety, OCD, PTSD, and substance use disorders). Status: CURRENT; Last review: 2026-05-01 (annual review approved April 27, 2026). Scope: applies to inpatient and outpatient IV infusion protocols (subanesthetic dosing, bolus followed by infusion) investigated for these indications. Key coverage position: IV anesthetics (ketamine, lidocaine) for chronic pain and for psychiatric or substance use disorders are considered investigational and are not covered for these indications.

    Surface quick facts
    Policy Number5.01.586
    StatusCURRENT
    Last Review2026-05-01
    ScopeIntravenous anesthetics (ketamine, lidocaine) for chronic pain and psychiatric or substance use disorders

    Medical Necessity / Investigational Determinations

    Investigational / Not Medically Necessary

    Intravenous infusion of anesthetics is considered investigational (unproven) for the following uses:

    ALL of the following

    • Intravenous infusion of anesthetics (e.g., ketamine or lidocaine) for the treatment of chronic pain, including but not limited to chronic neuropathic pain, chronic daily headache, and fibromyalgia.
    • Intravenous infusion of ketamine for the treatment of depression, anxiety, or other psychiatric symptoms or disorders, including substance use disorders.
    • Intravenous infusion of ketamine in conjunction with psychotherapy (ketamine-assisted therapy) for the treatment of depression, anxiety, or other psychiatric symptoms or disorders, including substance use disorders.
    ref
    title

    Coding

    CPT codes referencedCPT
    0820TContinuous in-person monitoring and intervention (e.g., psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour.
    0821TContinuous in-person monitoring and intervention ... second physician or other qualified health care professional, concurrent with first ... each hour (List separately in addition to code for primary procedure).
    0822TContinuous in-person monitoring and intervention ... clinical staff under the direction of a physician or other qualified health care professional, concurrent ... each hour.
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour.
    96366Each additional hour (list separately in addition to code for primary procedure).
    96374Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance/drug.
    HCPCS / J-codes referencedHCPCS
    J3490Unclassified drugs.
    Removed HCPCS code (history)HCPCS
    J2001Removed from policy; termed October 1, 2024.

    Provider Actions & Billing Impact

    Documentation Required

    Do not cover investigational uses

    Claims for IV infusion of anesthetics (for example, ketamine or lidocaine) when submitted for chronic pain (including chronic neuropathic pain, chronic daily headache, fibromyalgia) or for psychiatric or substance use disorders (including depression, anxiety, OCD, PTSD, and substance use disorders) are considered investigational and are not covered. Providers should document the indication on claims but should expect denials when these services are billed for these indications.

    • 0820T
    • 0821T
    • 0822T
    • 96365
    • 96366
    • 96374
    • J3490

    Provider guidance: If providers submit claims for IV ketamine or lidocaine for these investigational indications, they should document the specific indication in the claim; however, these uses are considered investigational and are not covered, and denials should be expected. The CPT and HCPCS codes listed in the policy (e.g., 0820T–0822T, 96365, 96366, 96374, J3490) may be used on claims but are not covered when billed for these investigational indications.

    Background & Evidence Summary

    Background: Intravenous lidocaine and ketamine have been investigated off-label for migraine and chronic daily headache, fibromyalgia, chronic neuropathic pain (including phantom limb pain, post-herpetic neuralgia, CRPS, diabetic neuropathy), and for treatment-resistant psychiatric disorders such as major depression and OCD. Typical protocols involve a series of IV infusions (subanesthetic doses with possible bolus) over days. Safety and durability concerns have been raised: adverse events can be serious (arrhythmias, seizures, dissociation, hallucinations, respiratory depression) and clinical trials have generally shown limited treatment durability.

    Evidence items
    Durable benefit for chronic painInsufficient — RCTs failed to show durable effect for lidocaine; limited temporary relief (2-4 weeks) in small ketamine trials.
    Treatment-resistant depression evidenceShort-term improvement in some trials; limited durability and concerns about controls/blinding; insufficient evidence for net health outcome improvement.
    Other psychiatric disorders (OCD, PTSD)Mixed RCT results and small case series; insufficient evidence for net health outcome improvement.

    Definitions / Glossary: • Chronic daily headache: headache occurring ≥15 days/month for ≥3 months (includes chronic migraine, new daily persistent headache, hemicrania continua, chronic tension-type headache). • Neuropathic pain: pain disproportionate to the triggering injury that may include allodynia, dysesthesia, or hyperalgesia and may persist ≥6 months after illness or injury. • Treatment-resistant depression: depression that does not respond adequately to appropriate courses of antidepressant medications.

    Medicare Determinations

    DeterminationDetails
    No national coverage determinationtype: NCD; number: ; effective:

    Revision History

    04/27/2026annual reviewLatest

    Annual review approved April 27, 2026. Policy updated with literature review through October 1, 2025; policy statements unchanged. Removed HCPCS code J2001 from policy (J2001 termed October 1, 2024).

    08/01/2018policy creation / replacement

    Initial policy approved July 10, 2018 and posted 08/01/18; this policy replaced prior policy 5.01.16 and the coverage criteria were amended to include IV ketamine for psychiatric symptoms and disorders.

    Policy Summary
    PayerPremera Bluecross
    PolicyIntravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders
    Policy CodePolicy 5.01.586
    Change TypeAnnual literature reviewcoding update
    Effective Date
    Last ReviewMay 1, 2026
    Next Review Date
    Key ActionClaims for IV infusion of anesthetics (e.g., ketamine, lidocaine) for chronic pain or psychiatric/substance use disorders are considered investigational and not covered; providers should document indication but expect denial if submitted for these indications.
    SourceLink
    On This Page
    Coverage SummaryMedical Necessity / Investigational DeterminationsCodingProvider Actions & Billing ImpactBackground & Evidence SummaryMedicare DeterminationsRevision History
    ref_raw_placeholder
    title_raw_placeholder

    Evidence synthesis: For chronic pain, randomized trials and reviews have not shown durable benefit (insufficient evidence); small ketamine trials suggest only limited, short-term relief. For treatment-resistant depression, trials show short-term improvement in some studies but limited durability and concerns about controls/blinding. For other psychiatric disorders (OCD, PTSD and similar), results are mixed and overall evidence is insufficient to demonstrate net health outcome improvement.